Marshall Wace, LLP Bei Gene, Ltd. Transaction History

Marshall Wace, LLP

$77.3 Billion
Q3 2024

A detailed history of Marshall Wace, LLP transactions in Bei Gene, Ltd. stock. As of the latest transaction made, Marshall Wace, LLP holds 45,939 shares of BGNE stock, worth $8.69 Million. This represents 0.01% of its overall portfolio holdings.

Number of Shares

45,939

Previous 51,987 11.63%

Holding current value

$8.69 Million

Previous $7.42 Million 39.06%

% of portfolio

0.01%

Previous 0.01%

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 14, 2024	SELL	$143.93 - $224.51 $870,488 - $1.36 Million	-6,048 Reduced 11.63%	45,939 $10.3 Million
Q2 2024 Aug 14, 2024	SELL	$129.52 - $174.32 $6.79 Million - $9.14 Million	-52,428 Reduced 50.21%	51,987 $7.42 Million
Q1 2024 May 15, 2024	BUY	$141.8 - $181.47 $5.18 Million - $6.63 Million	36,516 Added 53.78%	104,415 $16.3 Million
Q4 2023 Feb 14, 2024	BUY	$158.67 - $201.58 $10.8 Million - $13.7 Million	67,899 New	67,899 $12.2 Million
Q2 2022 Aug 15, 2022	SELL	$121.11 - $216.05 $3.17 Million - $5.65 Million	-26,134 Reduced 90.19%	2,842 $461,000
Q1 2022 May 16, 2022	BUY	$146.52 - $269.56 $1.94 Million - $3.56 Million	13,208 Added 83.76%	28,976 $5.47 Million
Q4 2021 Feb 14, 2022	BUY	$248.56 - $389.34 $3.92 Million - $6.14 Million	15,768 New	15,768 $4.27 Million
Q1 2021 May 17, 2021	SELL	$260.64 - $382.12 $19.3 Million - $28.3 Million	-74,117 Closed	0 $0
Q4 2020 Feb 16, 2021	BUY	$221.31 - $316.61 $16.4 Million - $23.5 Million	74,117 New	74,117 $19.2 Million
Q4 2018 Feb 14, 2019	SELL	$107.01 - $175.15 $3.97 Million - $6.49 Million	-37,061 Closed	0 $0
Q3 2018 Nov 14, 2018	BUY	$152.62 - $189.66 $5.66 Million - $7.03 Million	37,061 New	37,061 $6.38 Million

Others Institutions Holding BGNE

# of Institutions

249

Shares Held

45.3M

Call Options Held

292K

Put Options Held

119K

View Full List

About BeiGene, Ltd.

Ticker BGNE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 103,700,000
Market Cap $19.6B
Description
BeiGene, Ltd., a biotechnology company, focuses on discovering, developing, manufacturing, and commercializing various medicines worldwide. Its products include BRUKINSA to treat relapsed/refractory (R/R) mantle cell lymphoma; Tislelizumab to treat R/R classical Hodgkin's lymphoma; REVLIMID to treat multiple myeloma; VIDAZA to treat myelodysplas...

More about BGNE

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Marshall Wace, LLP, based on Form 13F filings with the SEC.

News

Stay updated on Marshall Wace, LLP with notifications on news.

Account

Marshall Wace, LLP Bei Gene, Ltd. Transaction History